1,800 Shares in Stevanato Group S.p.A. (NYSE:STVN) Purchased by Van Berkom & Associates Inc.

Van Berkom & Associates Inc. bought a new position in Stevanato Group S.p.A. (NYSE:STVN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,800 shares of the company’s stock, valued at approximately $39,000.

A number of other hedge funds have also added to or reduced their stakes in STVN. Hardy Reed LLC lifted its holdings in shares of Stevanato Group by 8.2% in the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock worth $222,000 after buying an additional 840 shares in the last quarter. Lindenwold Advisors INC lifted its stake in Stevanato Group by 13.5% in the 3rd quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock worth $239,000 after purchasing an additional 1,415 shares in the last quarter. Raymond James Trust N.A. boosted its holdings in Stevanato Group by 22.6% in the 3rd quarter. Raymond James Trust N.A. now owns 12,556 shares of the company’s stock valued at $251,000 after purchasing an additional 2,317 shares during the period. Captrust Financial Advisors boosted its holdings in Stevanato Group by 12.7% in the 3rd quarter. Captrust Financial Advisors now owns 13,100 shares of the company’s stock valued at $262,000 after purchasing an additional 1,480 shares during the period. Finally, First Bank & Trust grew its position in shares of Stevanato Group by 29.1% during the 3rd quarter. First Bank & Trust now owns 14,109 shares of the company’s stock valued at $282,000 after purchasing an additional 3,182 shares in the last quarter.

Stevanato Group Stock Down 0.2 %

Shares of NYSE:STVN opened at €20.31 ($21.38) on Friday. The firm has a fifty day moving average of €21.82 and a 200 day moving average of €20.53. Stevanato Group S.p.A. has a 52-week low of €16.56 ($17.43) and a 52-week high of €34.00 ($35.79). The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. The firm has a market capitalization of $6.15 billion, a PE ratio of 43.21, a price-to-earnings-growth ratio of 7.15 and a beta of 0.56.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Bank of America increased their price objective on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Wolfe Research started coverage on Stevanato Group in a report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price target on the stock. Finally, Morgan Stanley reissued an “equal weight” rating and set a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Stevanato Group currently has a consensus rating of “Moderate Buy” and a consensus price target of €28.60 ($30.11).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.